The decision to use 0.15 mg/kg once weekly for the large clinical trial was based on outcomes from shorter trials, cumulative dose, and the potential for similar efficacy with lower side effect risk compared to more frequent dosing, as suggested by the Everolimus study.

Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.

Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.

Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.

Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.

mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.

The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.